semaglutide · Novo Nordisk

What should I know about Wegovy?

Wegovy by Novo Nordisk: Weight, heart, MASH · pen and pill. Cost, side effects, dosing as labeled, comparisons and the latest news, all sourced.

Start hereWegovy FAQ: What People Ask Before and After StartingAnswers to the most-searched Wegovy questions in 2026, including the pill, the 7.2 mg HD dose, what it costs, why insurance dropped it, how much weight people lose and what happens when you stop.

FAQ

How-to guides

Side effects & safety

Stopping & switching

Compounded & telehealth

Alternatives

Results & daily life

Daily Life on a GLP-1: Work, Travel, Tracking and the Stuff Nobody Warns You AboutThe practical side of living on semaglutide or tirzepatide: dose day and work, travel and storage rules from the labels, tracking apps and what the research says about them, non-scale victories, stigma at work, and the daily-life questions nobody has studied yet.Exercise on GLP-1s: What the Evidence Actually ShowsStrength training and cardio while taking semaglutide or tirzepatide: what randomized trials, meta-analyses and society guidance say about muscle, results, and what happens after the drug stops — plus an honest map of what has never been tested.GLP-1 Plateau: Why Weight Loss Stalls and What the Research SaysPlateaus on semaglutide and tirzepatide are expected, measurable and well described in the trial data. Here is how researchers define a plateau, when it typically arrives, why it happens, and what the studies say about what comes next.How Fast Does Semaglutide Work? A Week-by-Week Reality CheckWhat the FDA label and the STEP trials actually show about how quickly semaglutide works, month by month — including the five-month milestone, when the curve flattens, and why real-world results run lower.How Fast Does Zepbound Work? What the Trial Curves ShowA month-by-month look at tirzepatide's weight-loss curve from SURMOUNT-1 and the FDA label — when the dose is reached, when most of the loss happens, when people plateau, and what happens to late responders.How Much Protein on a GLP-1? What Dietitians and the Research SayProtein targets on semaglutide and tirzepatide, where the numbers come from, why per-kilogram advice is confusing, what the body-composition data actually shows, and why protein alone will not do the job.

Getting started

Do I Qualify for Wegovy, Zepbound or Another GLP-1?A plain-English walk through who each FDA-approved GLP-1 is actually labeled for, where the BMI 30 and BMI 27 rules come from, what counts as a weight-related condition, and why your insurance plan may use stricter rules than the FDA label.How to Find an Obesity Medicine DoctorWhat obesity medicine certification actually means, the two free directories that list certified clinicians, how to verify a credential yourself, what these visits cost, and when a specialist is worth the extra step versus staying with primary care.How to Get a GLP-1 Prescription: Every Legitimate RouteThe six real ways to get an FDA-approved GLP-1 prescription in the US, what each one costs in time and money, what the FDA says about the sellers you should avoid, and how to verify anyone before you hand over a card number.Questions to Ask Your Doctor About GLP-1 MedicationThirty-one questions worth asking before and after you start a GLP-1, each one tied to something a specific FDA label, guideline recommendation or federal rule actually says, plus what a good answer sounds like.What to Expect Your First Month on a GLP-1Week by week through the starting dose, why it is deliberately too low to be a treatment dose, the side effect rates recorded in trials, the missed-dose rules that differ by product, and what the labels say should prompt a call to your clinician.Which GLP-1 Is Right for Me? How Doctors DecideWhat the guidelines actually say about choosing between semaglutide, tirzepatide, orforglipron and liraglutide, plus the seven practical factors that usually settle it, including the one clinicians rarely say out loud.

Cost & insurance

Medications

Pipeline

Foundayo

Specific groups

GLP-1 Drugs and Men's Health: Testosterone, Sex, Muscle and ResultsMen lose less percentage weight than women on the same dose, their testosterone tends to rise as they lose weight, the erectile function evidence points in two directions at once, and the muscle question is real. Here is what the 2025-2026 research actually found.GLP-1 Drugs for Teens: What Parents Should Know in 2026Two GLP-1 medicines are FDA-approved for adolescents with obesity, one is approved for children as young as 10 with type 2 diabetes, and none are approved under 12 for weight. Here is what the trials found, what the American Academy of Pediatrics guideline says, and what questions are still genuinely open.GLP-1s After Bariatric Surgery: What the Evidence Says in 2026Weight coming back after gastric sleeve or bypass is common, and adding semaglutide or tirzepatide is now one of the most-studied responses to it. A 2026 randomized trial and a 208,000-patient US cohort finally give real numbers - here is what they found, and what nobody has tested yet.GLP-1s and Menopause: What the Research Actually ShowsMenopause changes where your body stores fat and how much energy you burn, and GLP-1 drugs work in perimenopausal and postmenopausal women about as well as they work in younger women. The newer and more interesting question is whether menopause hormone therapy makes them work even better - here is what the evidence says, and what it does not say.GLP-1s for Type 1 Diabetes: What the Research Shows in 2026No GLP-1 or dual incretin drug is approved for type 1 diabetes anywhere, and the Wegovy label says use in type 1 diabetes has not been evaluated. But a randomized trial, a Danish national cohort and UK real-world data now exist - and they say something more specific than 'off-label.'GLP-1s Over 65: What the Data Actually ShowsNo GLP-1 label sets an age limit or an age-based dose, and trial analyses in adults 65 and older find efficacy close to younger adults. The real differences are tolerability, muscle and function, one specific fracture observation in the Wegovy label, and the fact that Medicare will not pay for weight loss.Who Should Not Take GLP-1 Drugs, According to the LabelsThe FDA labels for Wegovy, Ozempic, Zepbound and Mounjaro list exactly two absolute contraindications each. Everything else - pancreatitis, gallbladder disease, gastroparesis, pregnancy, surgery, eye disease - sits in warnings, 'not recommended' statements, and gaps where nobody has studied the question at all. Here is the actual list.

Market & policy

Insurance navigation

GLP-1 Prior Authorization: What Insurers Actually RequireWhat the published prior authorization criteria from UnitedHealthcare, CVS Caremark, Aetna, Cigna, Express Scripts and BCBS FEP actually say about BMI, comorbidities, lifestyle programs, step therapy, quantity limits and renewals — with the documents quoted and linked.How to Appeal a GLP-1 DenialHow to read a denial letter, tell an exclusion from a medical necessity denial, work through internal appeals, and use your right to an independent external review — with deadlines, required notice contents, and what the data says about your odds.How to Get Wegovy or Zepbound Covered by InsuranceA step-by-step process for finding out whether your plan covers a GLP-1 for weight loss, what it will require, and what to do at each fork in the road — written for the person holding the insurance card, not the prescription pad.HSA and FSA for GLP-1 DrugsWhether you can pay for Wegovy, Zepbound, Ozempic or a compounded GLP-1 with tax-free HSA or FSA money, when a letter of medical necessity is needed, what the tax deduction really requires, and how to work out whether to run a fill through insurance or pay cash.Medicaid Coverage of GLP-1s by StateWhich state Medicaid programs cover GLP-1s for obesity, which coverage is required in every state no matter what, what changed in 2025 and 2026, and how to check your own state's rules — plus how ACA Marketplace coverage compares.Medicare GLP-1 Bridge: How It WorksThe step-by-step mechanics of Medicare's GLP-1 Bridge demonstration: who qualifies, which products and devices are covered, how the prescription and prior authorization must be sequenced, what the $50 copay does and does not count toward, and why there is no appeal.Novo Nordisk and Lilly Patient Assistance Programs ExplainedWho actually qualifies for the Novo Nordisk Patient Assistance Program and the Lilly Cares Foundation, what the savings cards really cap out at, why a $25 card can turn into a $500 bill in month six, and how copay accumulators and alternative funding programs change the picture.Which Employers Cover GLP-1s?What the 2025 and 2026 employer surveys actually show about GLP-1 coverage, why the numbers disagree with each other, the strings employers attach, which state and federal plans cover the drugs, and how to find out what your own employer does.

How they work

Clinical trials

Culture

FDA & regulation

Companies

Liraglutide

News

Beyond weight loss

Recent Wegovy news

Full timeline
  1. Competition

    Novo Nordisk enters Capital Markets Day week holding 38.8% of the US branded obesity market

  2. Prices

    Status check: Novo Nordisk's $675 list price still lands well above every negotiated and cash price

  3. Prices

    Status check: the Zepbound formulary class action against CVS Caremark remains live as restoration nears

  4. Compounding

    Branded tirzepatide self-pay prices sit far below the shortage-era gap

  5. Competition

    Novo's Wegovy pill still outruns Foundayo roughly four to one

  6. Competition

    Wegovy pill and Foundayo both hit record weekly prescriptions

  7. FDA & regulation

    China approves Wegovy for MASH, the first GLP-1 cleared for the liver disease there

  8. Research

    Comparative review: tirzepatide wins on weight, not on tolerability